European stocks trading in the US moved sharply higher late Thursday morning, lifting the S&P Europe Select ADR Index by 2.21%. The gains were led by biotech and biopharma companies, with France's Cellectis surging 14% and Germany's BioNTech adding 4.5%.
American depositary receipts (ADRs) are US-traded certificates that represent shares in foreign companies. They allow US investors to buy and sell European stocks during American trading hours, often providing a preview of how those shares might trade when their home markets open. Thursday's rally signals strong demand for European equities among US-based investors, particularly in the life sciences sector.
Biotech Leads the Charge
Cellectis, a French clinical-stage biotech firm focused on gene-editing therapies, saw its ADR price jump 14% in late morning trading. The company has been a volatile name in recent months, but Thursday's move suggests renewed interest in its pipeline. BioNTech, the German biopharma giant best known for its COVID-19 vaccine partnership with Pfizer, rose 4.5%. The stock has been under pressure as vaccine demand wanes, but the gain hints at broader sector momentum.
Smaller life-sciences names also traded higher, contributing to the index's broad advance. The rally comes after a period of mixed performance for European stocks, with inflation cooling to 2.8% in June but energy prices remaining elevated. Healthcare and biotech have often been seen as defensive plays in uncertain economic times, and Thursday's move fits that pattern.
What Are ADRs and Why Do They Matter?
ADRs are a convenient way for US investors to diversify internationally without dealing with foreign exchanges, currency conversions, or different trading rules. Each ADR represents a specific number of shares in a non-US company, and its price tracks the underlying stock, adjusted for exchange rates. The S&P Europe Select ADR Index tracks a basket of these instruments, giving a snapshot of how European equities are faring in US markets.
Because European markets close hours before US trading begins, ADR movements can act as a leading indicator. A strong ADR session often translates into gains when the home market opens the next day. Thursday's 2.21% jump is a notable move for the index, which has seen periods of weakness earlier this year.
Broader Market Context
The rally in European ADRs comes amid a mixed backdrop for global markets. US factory growth slowed in June, with the ISM Manufacturing Index dipping to 53.3, though employment held steady. Meanwhile, European stocks rose 1.6% earlier in the week, led by healthcare and banks, as oil prices fell. The biotech sector's outperformance on Thursday suggests investors are rotating into growth-oriented healthcare names, possibly betting on new drug approvals or clinical trial results.
For everyday investors, the move highlights the importance of diversification. ADRs offer exposure to foreign markets without the complexity of direct international investing. However, they also carry currency risk: if the euro weakens against the dollar, ADR returns can be eroded even if the underlying stock price holds steady.
What It Means for Investors
Thursday's jump in European ADRs, especially in biotech, is a reminder that sector-specific news can drive outsized moves. Cellectis and BioNTech are both high-beta names—meaning they tend to swing more than the broader market—so their gains may not be sustainable. But the broad-based nature of the index rise suggests genuine demand for European equities, not just a few speculative bets.
Investors should watch for follow-through in European trading sessions. If the gains hold, it could signal a shift in sentiment toward the region, which has lagged US markets for much of the year. The biotech sector, in particular, may benefit from ongoing innovation in gene therapy and mRNA technology, though regulatory hurdles and competition remain risks.
As always, no single day's move should drive portfolio decisions. But for those with international exposure, Thursday's action is a positive sign that European stocks are finding buyers in US markets.
